AU2017216501A1 - Compositions for treating infections - Google Patents
Compositions for treating infections Download PDFInfo
- Publication number
- AU2017216501A1 AU2017216501A1 AU2017216501A AU2017216501A AU2017216501A1 AU 2017216501 A1 AU2017216501 A1 AU 2017216501A1 AU 2017216501 A AU2017216501 A AU 2017216501A AU 2017216501 A AU2017216501 A AU 2017216501A AU 2017216501 A1 AU2017216501 A1 AU 2017216501A1
- Authority
- AU
- Australia
- Prior art keywords
- composition
- copper
- weight
- skin
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 118
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 39
- 239000012528 membrane Substances 0.000 claims abstract description 25
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 108
- 150000003505 terpenes Chemical class 0.000 claims description 37
- -1 terpenoid compound Chemical class 0.000 claims description 37
- 235000007586 terpenes Nutrition 0.000 claims description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 30
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 28
- 239000004094 surface-active agent Substances 0.000 claims description 28
- 239000005749 Copper compound Substances 0.000 claims description 25
- 150000001880 copper compounds Chemical class 0.000 claims description 25
- 241000700605 Viruses Species 0.000 claims description 19
- 235000017309 Hypericum perforatum Nutrition 0.000 claims description 18
- 244000141009 Hypericum perforatum Species 0.000 claims description 17
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 14
- 241000196324 Embryophyta Species 0.000 claims description 14
- 229930003427 Vitamin E Natural products 0.000 claims description 14
- 235000011399 aloe vera Nutrition 0.000 claims description 14
- 239000000284 extract Substances 0.000 claims description 14
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 235000019165 vitamin E Nutrition 0.000 claims description 14
- 229940046009 vitamin E Drugs 0.000 claims description 14
- 239000011709 vitamin E Substances 0.000 claims description 14
- 239000000341 volatile oil Substances 0.000 claims description 14
- 244000144927 Aloe barbadensis Species 0.000 claims description 13
- 235000002961 Aloe barbadensis Nutrition 0.000 claims description 13
- 241000723346 Cinnamomum camphora Species 0.000 claims description 13
- 229930008380 camphor Natural products 0.000 claims description 13
- 229960000846 camphor Drugs 0.000 claims description 13
- 229940002386 calendula officinalis extract Drugs 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 241000700584 Simplexvirus Species 0.000 claims description 10
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 10
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 10
- 229920000053 polysorbate 80 Polymers 0.000 claims description 10
- 229940068968 polysorbate 80 Drugs 0.000 claims description 10
- 240000005636 Dryobalanops aromatica Species 0.000 claims description 9
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 8
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 8
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 8
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical group O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 claims description 8
- 229940041616 menthol Drugs 0.000 claims description 8
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 5
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 5
- 244000178231 Rosmarinus officinalis Species 0.000 claims description 5
- 241000233866 Fungi Species 0.000 claims description 4
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 4
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 4
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 4
- 235000009024 Ceanothus sanguineus Nutrition 0.000 claims description 3
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 claims description 3
- 244000004281 Eucalyptus maculata Species 0.000 claims description 3
- 240000003553 Leptospermum scoparium Species 0.000 claims description 3
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 229940116318 copper carbonate Drugs 0.000 claims description 3
- 229940108925 copper gluconate Drugs 0.000 claims description 3
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 claims description 3
- CMRVDFLZXRTMTH-UHFFFAOYSA-L copper;2-carboxyphenolate Chemical compound [Cu+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O CMRVDFLZXRTMTH-UHFFFAOYSA-L 0.000 claims description 3
- GEZOTWYUIKXWOA-UHFFFAOYSA-L copper;carbonate Chemical compound [Cu+2].[O-]C([O-])=O GEZOTWYUIKXWOA-UHFFFAOYSA-L 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 9
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 8
- 208000036142 Viral infection Diseases 0.000 description 8
- 238000011282 treatment Methods 0.000 description 7
- 230000009385 viral infection Effects 0.000 description 7
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 6
- 208000007514 Herpes zoster Diseases 0.000 description 6
- 241000701806 Human papillomavirus Species 0.000 description 6
- 229910052802 copper Inorganic materials 0.000 description 6
- 239000010949 copper Substances 0.000 description 6
- 239000008240 homogeneous mixture Substances 0.000 description 6
- 208000002474 Tinea Diseases 0.000 description 5
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 4
- 208000031888 Mycoses Diseases 0.000 description 4
- 206010039509 Scab Diseases 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 206010040882 skin lesion Diseases 0.000 description 4
- 231100000444 skin lesion Toxicity 0.000 description 4
- 201000010153 skin papilloma Diseases 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 240000001432 Calendula officinalis Species 0.000 description 3
- 206010017533 Fungal infection Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000130764 Tinea Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000010773 plant oil Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 201000004647 tinea pedis Diseases 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010005913 Body tinea Diseases 0.000 description 2
- 235000005881 Calendula officinalis Nutrition 0.000 description 2
- 244000192528 Chrysanthemum parthenium Species 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- 241000208152 Geranium Species 0.000 description 2
- 208000004898 Herpes Labialis Diseases 0.000 description 2
- 241000700586 Herpesviridae Species 0.000 description 2
- 241000934806 Krameria Species 0.000 description 2
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 2
- 206010067152 Oral herpes Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 206010043866 Tinea capitis Diseases 0.000 description 2
- 201000010618 Tinea cruris Diseases 0.000 description 2
- 206010067197 Tinea manuum Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000002280 amphoteric surfactant Substances 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 description 2
- QUQFTIVBFKLPCL-UHFFFAOYSA-L copper;2-amino-3-[(2-amino-2-carboxylatoethyl)disulfanyl]propanoate Chemical compound [Cu+2].[O-]C(=O)C(N)CSSCC(N)C([O-])=O QUQFTIVBFKLPCL-UHFFFAOYSA-L 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 229930003658 monoterpene Natural products 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- NDTYTMIUWGWIMO-UHFFFAOYSA-N perillyl alcohol Chemical compound CC(=C)C1CCC(CO)=CC1 NDTYTMIUWGWIMO-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 201000009642 tinea barbae Diseases 0.000 description 2
- 201000003875 tinea corporis Diseases 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 230000007332 vesicle formation Effects 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- 229930007631 (-)-perillyl alcohol Natural products 0.000 description 1
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 description 1
- 244000235603 Acacia catechu Species 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 101100327147 Arabidopsis thaliana CYCB1-5 gene Proteins 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241000245588 Baptisia Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101150058276 CYC3 gene Proteins 0.000 description 1
- 235000003880 Calendula Nutrition 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 241000723347 Cinnamomum Species 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 235000006965 Commiphora myrrha Nutrition 0.000 description 1
- 235000014493 Crataegus Nutrition 0.000 description 1
- 241001092040 Crataegus Species 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 244000133098 Echinacea angustifolia Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000832224 Hypericaceae Species 0.000 description 1
- 241000546188 Hypericum Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 240000007232 Illicium verum Species 0.000 description 1
- 235000008227 Illicium verum Nutrition 0.000 description 1
- 235000013628 Lantana involucrata Nutrition 0.000 description 1
- 240000005183 Lantana involucrata Species 0.000 description 1
- 244000165082 Lavanda vera Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 235000015511 Liquidambar orientalis Nutrition 0.000 description 1
- 235000000060 Malva neglecta Nutrition 0.000 description 1
- 240000000982 Malva neglecta Species 0.000 description 1
- 235000017945 Matricaria Nutrition 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 244000304222 Melaleuca cajuputi Species 0.000 description 1
- 235000001167 Melaleuca cajuputi Nutrition 0.000 description 1
- 235000017710 Melaleuca viridiflora Nutrition 0.000 description 1
- 241001480037 Microsporum Species 0.000 description 1
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 description 1
- 244000131360 Morinda citrifolia Species 0.000 description 1
- 235000008898 Morinda citrifolia Nutrition 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- 240000009023 Myrrhis odorata Species 0.000 description 1
- 240000005125 Myrtus communis Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- BUQLXKSONWUQAC-UHFFFAOYSA-N Parthenolide Natural products CC1C2OC(=O)C(=C)C2CCC(=C/CCC1(C)O)C BUQLXKSONWUQAC-UHFFFAOYSA-N 0.000 description 1
- 241000578507 Perforatus Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 235000016787 Piper methysticum Nutrition 0.000 description 1
- 240000005546 Piper methysticum Species 0.000 description 1
- 241001127637 Plantago Species 0.000 description 1
- 244000010922 Plantago major Species 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241001529742 Rosmarinus Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 239000004870 Styrax Substances 0.000 description 1
- 235000000126 Styrax benzoin Nutrition 0.000 description 1
- 244000028419 Styrax benzoin Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 241000404542 Tanacetum Species 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 240000003021 Tsuga heterophylla Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000005599 alkyl carboxylate group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002622 anti-tumorigenesis Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 description 1
- 150000001588 beta-ionone derivatives Chemical class 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 208000007287 cheilitis Diseases 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 235000000484 citronellol Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 125000000567 diterpene group Chemical group 0.000 description 1
- 235000014134 echinacea Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 244000078673 foodborn pathogen Species 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000017524 noni Nutrition 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- KTEXNACQROZXEV-PVLRGYAZSA-N parthenolide Chemical compound C1CC(/C)=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 KTEXNACQROZXEV-PVLRGYAZSA-N 0.000 description 1
- 229940069510 parthenolide Drugs 0.000 description 1
- 235000005693 perillyl alcohol Nutrition 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 150000003097 polyterpenes Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 235000015639 rosmarinus officinalis Nutrition 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 229930002368 sesterterpene Natural products 0.000 description 1
- 150000002653 sesterterpene derivatives Chemical class 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001273 sulfonato group Chemical class [O-]S(*)(=O)=O 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 239000010677 tea tree oil Substances 0.000 description 1
- 229940111630 tea tree oil Drugs 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 150000003535 tetraterpenes Chemical class 0.000 description 1
- 235000009657 tetraterpenes Nutrition 0.000 description 1
- 235000019529 tetraterpenoid Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Abstract
Abstract The present invention relates to compositions and in particular to compositions for treating a skin or mucosal membrane infection.
Description
COMPOSITIONS FOR TREATING INFECTIONS
Field of the invention [0001] The present invention relates to compositions and in particular to compositions for treating a skin or mucosal membrane infection.
Background ofthe invention [0002] Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of the common general knowledge in the field.
[0003] Microorganisms and viruses are responsible for a variety of diseases and disorders in humans and animals, including many dermatological disorders. Dermatophytes, for example, are a group of fungi that cause skin diseases in animals and humans. They include the genera Microsporum, Epidermophyton and Trichophyton. Tinea is a term used to describe a variety of skin mycoses including tinea pedis (commonly referred to as athlete's foot), tinea corporis (infections of the trunk, arms and legs), tinea manuum (infections of the finger webs), tinea cruris (infections of the groin), tinea barbae (infections of the neck) and tinea capitis (infections of the scalp).
[0004] Viruses are also responsible for a number of skin infections in animals and humans. Skin lesions such as warts, cold sores and shingles are often caused by viral infections. Most primary viral infections arise from one of three groups of viruses; poxviruses (poxviridae), herpesviruses (herpesviridae) and human papillomaviruses (papillomaviridae).
[0005] Common warts are a benign form of tumour typically caused by human papillomaviruses (HPV). Some strains of HPV, however, are also etiological agents in dysplasia and carcinomas in the oral and genital mucosa.
[0006] Molluscuum contagiosum is a type of poxvirus that causes skin lesions, sometimes referred to as water warts. Water warts are characterised by small, discrete, lobulated epidermal outgrowths that occur at various locations on the body.
2017216501 16 Aug 2017 [0007] Herpes zoster, commonly referred to as shingles, is a skin lesion caused by infection from the herpesviridae family of viruses. Shingles is often characterised by a painful rash and localised blistering which can last for several months.
[0008] Herpes Simplex Type 1 (HSV1) and Herpes Simplex Type 2 (HSV2) are etiological agents of cold sores and genital herpes, respectively. However, both types of herpes simplex virus (HSV) can be present on the mouth and genital areas, and it is possible for an individual to be infected by both HSV1 and HSV2. Infection by one strain does not render an individual immune to the other.
[0009] Recurrent outbreaks of HSV often follow a staged progression involving prodrome, vesicle formation, ulceration, crusting and healing. Prodrome is typically characterised by a short period of tingling, itching, numbness or burning with no clearly visible indication of an infection or outbreak. Vesicle formation involves the development of fluid-filled blisters, often in a cluster, and usually surrounded by sore, red skin. Ulceration occurs when the blisters open to form painful ulcers or open sores often with a yellow crust at the edges of the sore. At the crusting stage, weeping sores or ulcers are covered by a crust or scab. Healing involves the disappearance of the crust, swelling, pain and itching. Skin eruptions caused by viral infection, particularly HSV, generally have a normal infective course that lasts from between 10 and 60 days depending on the species of infective virus and the anatomical location of the infection.
[0010] After an initial outbreak of HSV, the virus may lie dormant in the skin or in nerve tissue until triggered to cause a new eruption or site infection. Triggers may include stress, fever, sunlight, hormonal changes or certain foods or drugs. When the virus is reactivated, it typically causes a sore at the site where it first entered the body.
[0011] Presently, there is no effective vaccine to prevent herpes infection. Moreover, the ability of the herpes virus to retreat into the nervous system makes it difficult to eliminate from the body. Systemic treatment of viral and fungal infections, although effective in some cases, may be associated with health risks including cardiac or hepatic toxicity, nausea, headaches and adverse drug interactions. Physical treatments such as cryotherapy, laser therapy and surgical removal, while also effective in some cases, can be painful and distressing, particularly for children, and may increase the likelihood of scar tissue formation. Topical antiviral formulations have also been developed, however, many suffer from problems such as poor stability leading to limited shelf-life,
2017216501 16 Aug 2017 susceptibility to freezing, poor active ingredient solubility or inefficient delivery of the active ingredient.
[0012] In this context, there is a need for alternative methods and compositions for treating skin and mucosal membrane infections, and in particular, infections caused by viruses and fungi. It is an object of the present invention to overcome or ameliorate at least one of the disadvantages of the prior art or to provide a useful alternative.
Summary of the invention [0013] In a first aspect, the present invention provides a composition for treating a skin or mucosal membrane infection the composition comprising:
glycerol;
at least one surfactant;
an alcohol;
a terpene or terpenoid compound; and a copper compound.
[0014] The terpene or terpenoid compound may be present in or extracted from an essential oil.
[0015] The essential oil may be obtained from a camphor laurel tree, a kapur tree, a rosemary plant, a mint plant, a eucalyptus tree or a tea tree.
[0016] Preferably, the terpene or terpenoid compound is camphor.
[0017] In one or more embodiments, the terpene or terpenoid compound is menthol.
[0018] In further embodiments, the terpene or terpenoid compound is camphor or menthol.
[0019] In another embodiment, the composition comprises camphorand menthol.
[0020] The copper compound is preferably selected from the group consisting of copper gluconate, copper carbonate, copper sulphate, copper chloride and copper salicylate.
2017216501 16 Aug 2017 [0021] The copper compound may be copper sulphate. Preferably, the copper sulphate is copper sulphate pentahydrate.
[0022] In one or more embodiments, the alcohol is isopropyl alcohol.
[0023] The composition may further comprise Hypericum perforatum extract.
[0024] The composition may further comprise Calendula officinalis extract.
[0025] In one or more embodiments, the composition further comprises aloe vera.
[0026] Preferably, the composition further comprises vitamin E.
[0027] The at least one surfactant preferably comprises polyethylene glycol.
[0028] The at least one surfactant may comprise polysorbate 80.
[0029] In one or more embodiments, the composition comprises substantially no water.
[0030] In another aspect, the present invention provides a method of producing a composition comprising the steps of:
i) combining glycerol and a copper compound to produce a glycerol solution;
ii) dissolving a terpene or terpenoid compound in an alcohol to produce an alcohol solution;
iii) combining the glycerol solution and the alcohol solution; and iv) adding at least one surfactant.
[0031] Step i) preferably includes heating the glycerol solution to about 80°C.
[0032] Preferably, step i) further comprises adding aloe vera to the glycerol solution.
[0033] In one or more embodiments, step iv) further comprises adding vitamin E, Hypericum perforatum extract and Calendula officinalis extract.
2017216501 16 Aug 2017 [0034] In another aspect, the present invention provides a method of treating a skin or mucosal membrane infection comprising topically applying the composition of the first aspect to the skin or mucosal membrane infection.
[0035] The skin or mucosal membrane infection may be caused by a bacterium, a virus or a fungus.
[0036] Preferably, the skin or mucosal membrane infection is caused by a virus.
[0037] The virus may be a Herpes Simplex Virus. Preferably, the virus is Herpes Simplex Virus 1 or Herpes Simplex Virus 2.
[0038] In another aspect, the present invention provides use of a composition of the first aspect in the manufacture of a medicament for the treatment of a skin or mucosal membrane infection.
[0039] In a further aspect, the present invention provides a composition of the first aspect for use in the treatment of a skin or mucosal membrane infection.
Detailed description of an embodiment of the invention [0040] Copper is known to possess antimicrobial and antiviral properties (eg, Sagripanti et al. (1997) Mechanism of Copper-Mediated Inactivation of Herpes Simplex Virus. Antimicrobial Agents and Chemotherapy 41(4): 812-817; Borkow and Gabbay (2009) Copper, an ancient remedy returning to fight microbial, fungal and viral infections. Curr. Chem. Biol. 3: 272-278). However, high concentrations of copper may cause blood poisoning which can potentially be fatal. Moreover, copper is prone to precipitation and, as such, is often formulated with relatively large volumes of water. In contrast, the present inventors have surprisingly found that compositions comprising copper and a terpene or terpenoid compound, in addition to glycerol, a surfactant and an alcohol, can be formulated with little or no water and that such compositions are effective in the treatment of skin and mucosal membrane infections. Accordingly, compositions of the present invention comprise:
glycerol;
at least one surfactant;
2017216501 16 Aug 2017 an alcohol;
a terpene or terpenoid compound; and a copper compound.
[0041] A number of different copper compounds may be used in accordance with the present invention. The copper compound may be a copper (I) compound or a copper (II) compound. In one or more embodiments, the copper compound is copper gluconate, copper carbonate, copper sulphate, copper chloride or copper salicylate. Preferably, the copper compound is copper sulphate and, more preferably, copper sulphate pentahydrate.
[0042] The composition may comprise from about 1% to about 10% by weight of the copper compound. Preferably, the composition comprises less than about 5% of the copper compound, such as from about 2% to about 4% by weight of the copper compound and, preferably, about 3% by weight of the copper compound.
[0043] The composition preferably includes a skin protectant such as glycerol. Glycerol may form a barrier over the skin and protect against irritation caused by touching, scratching, rubbing and the like. It may also provide a protective barrier over the lesion, preventing loss of the active ingredient. In one or more embodiments, the composition comprises at least 20% by weight of glycerol, such as at least 30% by weight, at least 35% by weight, at least 40% by weight, at least 45% by weight or, more preferably, at least 50% by weight of glycerol.
[0044] The composition preferably includes a terpene or terpenoid compound. Terpenes and terpenoids are diverse classes of organic compounds that are widespread in nature, particularly in plants, plant parts or plant oils, from which they may be extracted. Terpenes and terpenoids can also be synthesised. Terpenes and terpenoids have been shown to possess antimicrobial properties (eg, Chaumont and Leger (1992) Campaign Against Allergic Moulds in Dwellings, Inhibitor Properties of Essential Oil Geranium Bourbon Citronellol, Geraniol and Citral. Ann. Pharm. Fr. 50(3): 156-166; Mikhlin et al. (1983) Antifungal and Antimicrobial Activity of Some Derivatives of BetaIonone and Vitamin A. Prikl Biokhim Mikrobiol 19: 795-803; Kim et al. (1995) Antibacterial Activity of Some Essential Oil Components Against Five Foodborne Pathogens. J. Agri. Food Chem. 43: 2839-2845; Isman (2000) Plant essential oils for
2017216501 16 Aug 2017 pest and disease management. Crop Protection. 19: 603-608). They have also been associated with the effective treatment of tumors (eg, Crowell et al. (1996) Antitumorigenic Effects of Limonene and Perillyl Alcohol Against Pancreatic and Breast Cancer. Adv. Exp. Med. Biol. 401: 131-136) and the lowering of cholesterol levels (eg, Elson et al. (1994) The Chemoprevention of Cancer by Melavonate-Derived Constituents of Fruits and Vegetables. J. Nutr. 124: 607-614).
[0045] The building block of terpenes and terpenoids is the C-5 hydrocarbon, isoprene (C5H8). The isoprene building blocks may be joined in a head-to-tail arrangement, thereby forming linear or branched chains, or they may be arranged as a ring. Whereas terpenes are generally hydrocarbons, terpenoids often contain additional functional groups. Terpenoids may result from the modification of a terpene such as when a methyl group has been moved or removed, or when an oxygen or other functional group has been added. However, the term terpene is often used interchangeably with the term terpenoid.
[0046] The terpene or terpenoid compound may be present in, or extracted from, an essential oil. Essential oils are typically extracted from plants, or plant parts, and may comprise a volatile mixture of esters, alcohols, vitamins, aldehydes, ketones, terpenes and terpenoids. They are usually hydrophobic and immiscible in water. They may, however, be soluble in certain oils and organic solvents such as alcohols or acetone. Essential oils for use in the present invention may be extracted from, for example, a camphor laurel tree, a kapur tree, a rosemary plant, a mint plant, a eucalyptus tree or a tea tree. Other sources of essential oils may include Plantago (eg, Plantago major), Hypericum (eg, Hypericaceae perforatus), Baptisia, Calendula (eg, Calendular officinalis), myrrh, echinacea (eg, Echinaceae angustifoliae radix or Echinaceae purpurea), Phytolaca, Salvia, Tsuga, Styrax, Catechu black, Krameria, Crataegus, Glycerrhiza (eg, Glycerrhiza glabra), Angelica, Krameria, Matricaria, Mallow, sage, chamomile, Hammamelis, aloe vera, nettle. Kava Kava, Noni fruit (Morinda citrifolia), Feverfew (eg, Tanacetum parthenolide), Astragulus, cinnamon, cajeput, fennel, geranium, girofle, lavender, lemon, myrte, oregano, pine, sarriette, thyme, Pinus, Star anise and garlic.
[0047] Terpenes that may be suitable for use in accordance with the present invention include, for example, hemiterpenes, monoterpenes, sesquiterpenes, diterpenes, sesterterpenes, triterpenes, sesquarterpenes, tetraterpenes and polyterpenes.
2017216501 16 Aug 2017
Terpenoids that may be suitable for use in accordance with the present invention include, for example, hemiterpenoids, monoterpenoids, sesquiterpenoids, diterpenoids, sesterterpenoids, triterpenoids, tetraterpenoids and polyterpenoids. In one or more embodiments, the terpene or terpenoid compound of the present invention is camphor (Ci0H16O). Camphor may be synthesised or it may be extracted from a plant oil such as the oil of the camphor laurel tree (Cinnamomum camphora), the kapur tree or rosemary (Rosmarinus officinalis). The camphor is preferably provided in a powder or granulated form such as tablets. In further embodiments, the terpene or terpenoid compound is menthol (C10H2oO). Menthol may be synthesised or it may be extracted from a plant oil such as the oil of mint.
[0048] Compositions of the present invention preferably comprise between about 0.5% and 5% of the terpene or terpenoid compound by weight. Preferably, the composition comprises between about 1% and 4%, between about 1.5% and 3.5%, between about 2% and 3.5% or, more preferably, about 3% of the terpene or terpenoid compound by weight.
[0049] Those skilled in the art will understand that a variety of different alcohols may be used in accordance with the present invention. In one or more embodiments, the alcohol is a CrC6 alcohol and, preferably, a CYC3 alcohol. The alcohol may, for example, be ethanol or, preferably, isopropyl alcohol. The alcohol may be present in the composition in an amount of between about 10% and 50% by weight, such as between about 20% and 45% by weight or between about 25% and 40% by weight. Preferably, the alcohol is present at a concentration of about 35% by weight.
[0050] The composition preferably comprises a surfactant, and in some embodiments, more than one surfactant. A surfactant is a surface active agent that can act to stabilise an emulsion. Surfactants typically comprise a molecule having a polar or charged, hydrophilic head group and a hydrophobic tail group. Those skilled in the art will understand that compositions of the present invention may be formulated using one or more of a variety of surfactants. The surfactant may be an ionic, non-ionic or zwitterionic surfactant. Surfactants suitable for use in the compositions of the present invention may include anionic, cationic, amphoteric and non-ionic surfactants. Nonlimiting examples of anionic surfactants include sulfate esters, sulfonate esters, phosphate esters and alkyl carboxylates. Non-limiting examples of cationic surfactants include quaternary ammonium compounds, such as cetyl trimethylammonium bromide,
2017216501 16 Aug 2017 cetylpyridinium chloride, benzethonium chloride and dioctadecyldimethylammonium bromide. Non-limiting examples of amphoteric surfactants include betaines, imino acetates and imino propionates. Non-limiting examples of non-ionic surfactants include fatty alcohols, glucosides, maltosides, polyethoxylated tallow amines, cocoamides, sorbitan alkyl esters, block copolymers of polyethylene glycol and polypropylene glycol, ethoxylated amines and ethoxylated alcohols. The composition of the present invention may comprise between about 1% and 10% by weigh of a surfactant such as between about 3% and 9% by weight or between about 4% and 8% by weight of a surfactant.
[0051] In one or more embodiments, the composition of the present invention comprises polysorbate 80 and polyethylene glycol 400 (PEG400). Preferably, the composition comprises polysorbate 80 at a concentration of between about 0.05% and 1% by weight such as between about 0.1% and 0.5% by weight. Preferably, the composition comprises polysorbate 80 at a concentration of about 0.2% by weight. The composition may also comprise PEG400 at a concentration of between about 1% and 10% by weight such as between about 2% and 7% by weight or between about 4% and 6% by weight. Preferably, the composition comprises PEG400 at a concentration of about 5% by weight.
[0052] In one embodiment, the composition for treating a skin or mucosal membrane infection of the present invention comprises:
glycerol in an amount of between about 30% and 80% by weight;
at least one surfactant in an amount of between about 1% and 10% by weight;
an alcohol in an amount of between about 20% and 60% by weight;
a terpene or terpenoid compound in an amount of between about 0.5% and 5% by weight; and a copper compound in an amount of between about 1% and 10% by weight.
[0053] In another embodiment, the composition for treating a skin or mucosal membrane infection of the present invention comprises:
glycerol in an amount of between about 30% and 60% by weight;
2017216501 16 Aug 2017 at least one surfactant in an amount of between about 1% and 10% by weight;
an alcohol in an amount of between about 20% and 50% by weight;
a terpene or terpenoid compound in an amount of between about 0.5% and 10% by weight; and a copper compound in an amount of between about 1% and 5% by weight.
[0054] In another embodiment, the composition for treating a skin or mucosal membrane infection of the present invention comprises:
glycerol in an amount of at least about 35% by weight;
at least one surfactant in an amount of between about 1% and 10% by weight;
an alcohol in an amount of between about 10% and 50% by weight;
a terpene or terpenoid compound in an amount of between about 0.5% and 5% by weight; and a copper compound in an amount of between about 1% and 5% by weight.
[0055] In another embodiment, the composition comprises:
glycerol in an amount of at least about 40% by weight;
at least one surfactant in an amount of between about 3% and 7% by weight;
an alcohol in an amount of between about 25% and 40% by weight;
a terpene or terpenoid compound in an amount of between about 1% and 4% by weight; and a copper compound in an amount of between about 2% and 4% by weight.
[0056] In a further embodiment, the composition comprises:
glycerol in an amount of at least about 40% by weight;
at least one surfactant in an amount of about 5% by weight;
2017216501 16 Aug 2017 an alcohol in an amount of about 35% by weight;
a terpene or terpenoid compound in an amount of about 3% by weight; and a copper compound in an amount of about 3% by weight.
[0057] The composition may further comprise one or more herbal extracts such as Hypericum perforatum and/or Calendula officinalis extract. Hypericum perforatum and Calendula officinalis extracts have antimicrobial and antiviral activity (Clewell et al. Efficacy and tolerability assessment of a topical formulation containing sulfate and Hypericum perforatum on patients with herpes skin lesions: a comparative, randomized controlled trial. Journal of Drugs in Dermatology 11(2): 209-215; Wolfe et al. Topical application of St. John's Wort (Hypericum perforatum). Planta Med. 80: 109-120; Roveroni-Favaretto et al. Topical Calendula officinalis L. successfully treated exfoliative cheilitis: a case report. Cases Journal. 2: 9077) and can be obtained from various parts of the plant, including flowers, leaves, seeds, roots and stems. The extracts can be prepared using distillation, pressing, or solvent (eg, ethanol) extraction. In one or more embodiments, the Hypericum perforatum extract is present in the composition at a concentration of about 1% by weight or less such as about 0.5% by weight or less, 0.25% by weight or less or 0.1% by weight or less. Preferably, the Hypericum perforatum extract is present in the composition at a concentration of about 0.05% by weight. In one or more embodiments, the Calendula officinalis extract is present in the composition at a concentration of about 1% by weight or less such as about 0.5% by weight or less, 0.25% by weight or less or 0.1% by weight or less. Preferably, the Calendula officinalis extract is present in the composition at a concentration of about 0.05% by weight.
[0058] In one embodiment, the composition comprises:
glycerol in an amount of at least about 40% by weight;
at least one surfactant in an amount of about 5% by weight;
an alcohol in an amount of about 35% by weight;
a terpene or terpenoid compound in an amount of about 3% by weight;
a copper compound in an amount of about 3% by weight; and
2017216501 16 Aug 2017
Hypericum perforatum extract in an amount of between about 0.01% and 2% by weight.
[0059] In a further embodiment, the composition comprises:
glycerol in an amount of at least about 40% by weight;
at least one surfactant in an amount of about 5% by weight;
an alcohol in an amount of about 35% by weight;
a terpene or terpenoid compound in an amount of about 3% by weight;
a copper compound in an amount of about 3% by weight;
Hypericum perforatum extract in an amount of between about 0.01% and 2% by weight; and
Calendula officinalis extract in an amount of between about 0.01% and 2% by weight.
[0060] In one or more embodiments, the composition of the present invention includes Vitamin E. Vitamin E may be present in, or extracted from, an essential oil. The vitamin E is preferably present at a concentration of 1% or less by weight, 0.5% or less by weight or 0.25% or less by weight. Preferably, the vitamin E is present at a concentration of about 0.1% by weight.
[0061] In some embodiments, the composition further comprises aloe vera. Aloe vera is obtained from plants of the genus Aloe, such as Aloe barbadensis plants. In one or more embodiments, the aloe vera is present in the composition at a concentration of about 1% by weight or less, about 0.5% or less by weight, about 0.25% or less, about 0.1% or less by weight, about 0.05% or less by weight or about 0.025% or less by weight. Preferably, the aloe vera is present at a concentration of about 0.01% by weight.
[0062] In one embodiment, the composition comprises:
glycerol in an amount of between about 30% and 80% by weight;
at least one surfactant in an amount between about 1% and 10% by weight;
2017216501 16 Aug 2017 an alcohol in an amount between about 20% and 60% by weight;
a terpene or terpenoid compound in an amount between about 0.5% and 5% by weight;
a copper compound in an amount between about 1% and 10% by weight;
Hypericum perforatum extract in an amount of between about 0.01% and 2% by weight;
Calendula officinalis extract in an amount of between about 0.01% and 2% by weight;
vitamin E in an amount of between about 0.01% and 2%; and aloe vera in an amount of between about 0.01% and 2%.
[0063] The present inventors have surprisingly found that compositions of the present invention can be prepared with no, or substantially no, water. Accordingly, the composition may be a non-aqueous composition. The compositions were observed to form stable, homogenous mixtures. The composition may be stable for at least 3 months, such as for 6 months, 9 months, 12 months, 15 months, 18 months or 21 months. Preferably, the composition is stable for 24 months.
[0064] In one or more embodiments, the composition of the present invention has a pH of less than about 7, such as less than about 6, less than about 5, less than about 4 or less than about 3. The pH of the composition may be between about 1 and 4 or between about 1.5 and 3.5. Preferably, the pH of the composition is between about 2 and 2.5.
[0065] In one or more embodiments, the composition of the present invention has a density (SG) of between about 0.25 g/mL and 2 g/ml_, such as between about 0.5 g/mL and 1.5 g/mL or between about 0.75 g/mL and 1.25 g/mL. Preferably, the density of the composition is between about 1 g/mL and 1.1 g/mL.
[0066] In one or more embodiments, the composition of the present invention has a viscosity of between about 100 cps and 500 cps, such as between about 150 cps
2017216501 16 Aug 2017 and 400 cps or between about 200 cps and 350 cps. Preferably, the viscosity of the composition is between about 225 cps and 300 cps.
[0067] The composition may comprise further ingredients that are suitable for the topical treatment of skin or mucosal membrane infections. For example, the composition may further comprise, inter alia, preservatives, thickeners, osmotic regulators, flavours, fragrances, emollients, humectants, colorants pigments or pharmaceutically acceptable carriers. The composition may also comprise stabilisers such as propylene glycol which may be present at a concentration of between about 5% and 25% by weight or, preferably, between about 10% and 20% by weight.
[0068] In preferred embodiments, the composition is a homogenous composition. The composition is preferably suitable for topical formulation. The composition may be formulated as a cream, a lotion, a paste, an emollient, a gel, a foam or an emulsion.
[0069] The term emulsion as used herein includes droplets, dispersions or other structures that form when two or more immiscible liquids are combined. An emulsion may be prepared by simple stirring and without the use of high shear mixers. Alternatively, emulsions having smaller droplet sizes may be prepared using high pressures and/or high shear forces. Microemulsions generally comprise droplets having a diameter range from about 1000 nm to about 500 urn. Nanoemulsions, on the other hand, comprise smaller droplets with a diameter of less than about 1000 nm.
[0070] The composition may be used to treat a skin or mucosal membrane infection, and preferably, a viral infection. The infection may be caused by a poxvirus, a herpesvirus or a human papillomavirus. In some embodiments, the viral infection is caused by herpes simplex virus, herpes zoster virus, Molluscuum contagiosum, human papillomavirus, polio virus, shingles-associated viruses, varicella zoster virus, chicken pox-associated viruses or human immunodeficiency virus. Preferably, the viral infection is caused by herpes simplex virus.
[0071] Those skilled in the art will understand that the compositions of the present invention are also useful for treating other skin or mucosal membrane infections. For example, the composition may be used to treat a fungal infection, such as tinea. The form of tinea may be, for example, tinea pedis, tinea corporis, tinea manuum, tinea cruris, tinea barbae or tinea capitis.
2017216501 16 Aug 2017 [0072] The term pharmaceutically acceptable as used herein refers to substances that do not cause substantial adverse allergic or immunological reactions when administered to a subject. A pharmaceutically acceptable carrier includes, but is not limited to, solvents, coatings, dispersion agents, wetting agents, isotonic and absorption delaying agents and disintegrants.
[0073] The term substantially no as used in reference to water content means that water constitutes less than about 2% by weight such as less than 1% by weight, preferably less than 0.5% by weight or, more preferably, less than 0.1% by weight.
[0074] The terms comprise, comprises, comprised or comprising, including or having and the like in the present specification and claims are used in an inclusive sense, ie, to specify the presence of the stated features but not preclude the presence of additional or further features.
[0075] In the context of this specification the term about is understood to refer to a range of +/- 10%, preferably +/- 5% or +/-1% or, more preferably, +/- 0.1%.
[0076] In the context of this specification the terms a and an are used herein to refer to one or to more than one (i.e to at least one) of the grammatical object of the article. By way of example, an element means one element or more than one element.
Example 1 [0077] A composition suitable for treating a skin or mucosal membrane infection was prepared as set out in Table 1 below.
Table 1
Ingredient | %w/w |
Glycerol | 40 |
Cupric sulphate pentahydrate | 3 |
Camphor tablets | 3 |
Isopropyl alcohol | 35 |
PEG400 | 5 |
Polysorbate 80 | 0.2 |
Vitamin E | 0.1 |
Glycerol | To 100 |
2017216501 16 Aug 2017
Example 2 [0078] A composition suitable for treating a skin or mucosal membrane infection was prepared as set out in Table 2 below.
Table 2
Ingredient | %w/w |
Glycerol | 40 |
Cupric sulphate pentahydrate | 3 |
Aloe Vera 200:1 | 0.01 |
Camphor tablets | 3 |
Isopropyl alcohol | 35 |
PEG400 | 5 |
Polysorbate 80 | 0.2 |
Vitamin E | 0.1 |
Hypericum perforatum extract | 0.05 |
Calendula officinalis extract | 0.05 |
Glycerol | To 100 |
[0079] In addition to the composition shown in Table 2, compositions comprising between 1% and 4% camphor and between 1% and 5% cupric sulphate were also prepared. The compositions formed a stable, homogenous mixture.
Example 3 [0080] Additional compositions, based on that shown in Table 2, were produced in which camphor was replaced with the following alternative terpene/terpenoid compounds or essential oils:
2017216501 16 Aug 2017
Example 4
Table 3
Terpenoid/Essential oil | %w/w |
Menthol | 1-4 |
Tea tree oil | 1-4 |
Eucalyptus oil | 1-4 |
[0081] Further compositions suitable for treating a skin or mucosal membrane infection were prepared as set out in Table 4.
Table 4
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | |
Ingredients | %w/w | ||||||||||
Glycerol | 40-60 | 42-62 | 44-64 | 46-66 | 48-68 | 49-69 | 50-70 | 51 -72 | 52-72 | 50-70 | 40-60 |
Copper Salt (Cupric sulphate pentahydrate) | 2.5 | 2.6 | 2.7 | 2.8 | 2.9 | 3.0 | 3.1 | 3.5 | 3.5 | 3.6 | 2.5 |
Camphor | 2.5 | 2.6 | 2.7 | 2.8 | 2.9 | 3.0 | 3.1 | 3.5 | 3.5 | 3.6 | 2.5 |
Isopropyl alcohol | 20-45 | 21 -44 | 22-42 | 24-40 | 26-38 | 25-37 | 26-36 | 28-34 | 30-34 | 30-34 | 20-45 |
Polysorbate 80 | 0.1 | 0.2 | 0.3 | 0.4 | 0.5 | 0.6 | 0.2 | 0.2 | 0.3 | 0.2 | 0.1 |
Vitamin E | 0.1 | 0.2 | 0.3 | 0.4 | 0.5 | 0.6 | 0.4 | 0.3 | 0.4 | 0.3 | 0.1 |
Calendula officinalis extract | 0.01 | 0.02 | 0.03 | 0.04 | 0.05 | 0.06 | 0.04 | 0.03 | 0.04 | 0.03 | 0.00 |
Aloe vera | 0.1 | 0.2 | 0.3 | 0.4 | 0.5 | 0.6 | 0.4 | 0.4 | 0.3 | 0.2 | 0.00 |
Hypericum perforatum extract | 0.01 | 0.02 | 0.03 | 0.04 | 0.05 | 0.06 | 0.04 | 0.02 | 0.03 | 0.02 | 0.00 |
PEG400 | 1.0 | 2.0 | 3.0 | 4.0 | 5.0 | 6.0 | 5.0 | 4.0 | 5.0 | 6.0 | 1.0 |
Menthol | 0.1 | - | 0.2 | - | 0.1 | 0.2 | - | 0.1 | 0.2 | 0.3 | 0.2 |
Water / Glycerol | to 100 | to 100 | to 100 | to 100 | to 100 | to 100 | to 100 | to 100 | to 100 | to 100 | to 100 |
[0082] The compositions formed a stable, homogenous mixture.
Example 5 [0083] The composition shown in Table 1 was prepared by the following step-wise process:
2017216501 16 Aug 2017
Step 1
Glycerol and cupric sulphate pentahydrate were mixed until completely dissolved. To assist dissolution, the mixture was heated to 80°C. If particulate matter was observed, it was removed by filtration.
Step 2
Camphor tablets were ground into a powder and dissolved in isopropyl alcohol.
Step 3
PEG400, polysorbate 80 and vitamin E were combined to form a homogenous mixture.
[0084] The compositions produced by steps 1 to 3 were combined and mixed until homogenous. Further glycerol was added as appropriate. To avoid isopropyl alcohol loss, the final composition was stored in a sealed container at a temperature of below 25°C.
Example 6 [0085] The composition shown in Table 2 was prepared by the following step-wise process:
Step 1
Glycerol, cupric sulphate pentahydrate and aloe vera were mixed until completely dissolved. To assist dissolution, the mixture was heated to 80°C. If particulate matter was observed, it was removed by filtration.
Step 2
Camphor tablets were ground into a powder and dissolved in isopropyl alcohol.
Step 3
PEG400, polysorbate 80, vitamin E, Hypericum perforatum extract and Calendula officinalis extract were combined to form a homogenous mixture.
2017216501 16 Aug 2017
The compositions produced by steps 1 to 3 were combined and mixed until homogenous. Further glycerol was added as appropriate. To avoid isopropyl alcohol loss, the final composition was stored in a sealed container at a temperature of below 25°C.
Example 7 [0086] A composition based on that described in Example 2 was prepared as a 10 kg batch. 0.5 mL aliquots were prepared for stability testing. Each aliquot was stored in a clear glass vial at 30°C I 65% relative humidity. The composition formed a homogenous mixture with a pH of between about 1.5 and 3.5, a density (SG) of between about 1 g/mL and 1.1 g/mL, and a viscosity of between about 225 cps and 300 cps (S#3, 12 rpm, at 20°C) which was stable for more than 12 months.
[0087] Although the invention has been described with reference to specific embodiments, it will be appreciated by those skilled in the art that the invention may be embodied in many other forms.
Claims (25)
- Claims1. A composition for treating a skin or mucosal membrane infection the composition comprising:glycerol;at least one surfactant;an alcohol;a terpene or terpenoid compound; and a copper compound.
- 2. The composition of claim 1 wherein the terpene or terpenoid compound is present in or extracted from an essential oil.
- 3. The composition of claim 2 wherein said essential oil is obtained from a camphor laurel tree, a kapur tree, a rosemary plant, a mint plant, a eucalyptus tree or a tea tree.
- 4. The composition of any one of the preceding claims wherein the terpene or terpenoid compound is camphor.
- 5. The composition of any one of claims 1 to 3 wherein the terpene or terpenoid compound is menthol.
- 6. The composition of any one of the preceding claims wherein the copper compound is selected from the group consisting of copper gluconate, copper carbonate, copper sulphate, copper chloride and copper salicylate.
- 7. The composition of claim 6 wherein the copper compound is copper sulphate.
- 8. The composition of claim 7 wherein the copper sulphate is copper sulphate pentahydrate.
- 9. The composition of any one of the preceding claims wherein the alcohol is isopropyl alcohol.2017216501 16 Aug 2017
- 10. The composition of any one of the preceding claims further comprising Hypericum perforatum extract.
- 11. The composition of any one of the preceding claims further comprising Calendula officinalis extract.
- 12. The composition of any one of the preceding claims further comprising aloe vera.
- 13. The composition of any one of the preceding claims further comprising vitamin E.
- 14. The composition of any one of the preceding claims wherein the at least one surfactant comprises polyethylene glycol.
- 15. The composition of any one of the preceding claims wherein the at least one surfactant comprises polysorbate 80.
- 16. The composition of any one of the preceding claims wherein the composition comprises substantially no water.
- 17. A method of producing a composition comprising the steps of:i) combining glycerol and a copper compound to produce a glycerol solution;ii) dissolving a terpene or terpenoid compound in an alcohol to produce an alcohol solution;iii) combining the glycerol solution and the alcohol solution; and iv) adding at least one surfactant.
- 18. The method of claim 17 wherein step i) includes heating the glycerol solution to about 80°C.
- 19. The method of claim 17 or claim 18 wherein step i) further comprises adding aloe vera to the glycerol solution.2017216501 16 Aug 2017
- 20. The method of any one of claims 17 to 19 wherein step iv) further comprises adding vitamin E, Hypericum perforatum extract and Calendula officinalis extract.
- 21. A method of treating a skin or mucosal membrane infection comprising topically applying the composition of any one of claims 1 to 16 to the skin or mucosal membrane infection.
- 22. The method of claim 21 wherein the skin or mucosal membrane infection is caused by a bacterium, a virus or a fungus.
- 23. The method of claim 22 wherein the skin or mucosal membrane infection is caused by a virus.
- 24. The method of claim 23 wherein the virus is a Herpes Simplex Virus.
- 25. The method of claim 24 wherein the virus is Herpes Simplex Virus 1 or Herpes Simplex Virus 2.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2017216501A AU2017216501A1 (en) | 2017-08-16 | 2017-08-16 | Compositions for treating infections |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2017216501A AU2017216501A1 (en) | 2017-08-16 | 2017-08-16 | Compositions for treating infections |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2017216501A1 true AU2017216501A1 (en) | 2019-03-07 |
Family
ID=65528947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2017216501A Abandoned AU2017216501A1 (en) | 2017-08-16 | 2017-08-16 | Compositions for treating infections |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2017216501A1 (en) |
-
2017
- 2017-08-16 AU AU2017216501A patent/AU2017216501A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6823622B2 (en) | Pharmaceutical composition containing crude drugs (land) | |
Moga et al. | An overview on the anticancer activity of Azadirachta indica (Neem) in gynecological cancers | |
US7858570B2 (en) | Compositions and methods for removing urushiol and treating the resulting skin condition | |
KR101812746B1 (en) | Formulations containing extracts of echinacea angustifolia and zingiber officinale which are useful in reducing inflammation and peripheral pain | |
US9775872B2 (en) | Topical pharmaceutical bases for preventing viral diseases | |
US20100303935A1 (en) | Medicinal Composition | |
US11510866B2 (en) | Compositions for treating infections | |
JP6966998B2 (en) | Formulations for the treatment of oral, throat and airway disorders | |
CN112423771B (en) | Virus inactivating agent | |
KR20170036058A (en) | Cineole-containing composition for nasal application | |
CN103301065A (en) | Nasal spray of seaweed extract and preparation method of nasal spray | |
AU2017216501A1 (en) | Compositions for treating infections | |
CA2976564A1 (en) | Compositions for treating infections | |
CN114558052B (en) | D-limonene nanoemulsion synergistic composition for preventing oral cancer and preparation method and application thereof | |
AU742780B2 (en) | Herbal anti-viral agent | |
CN106822321B (en) | Application of Curcuma water of traumatology in preparing medicine for treating keratosis pilaris | |
Pintas et al. | Natural products that exhibit antifungal activity | |
Sifour et al. | Burn healing activity of aqueous extract of Atractylis gummifera (L) | |
RU2600795C1 (en) | Vegetable composition in the form of a micellar solution | |
US10045952B2 (en) | Anti-Viral Compound and Composition | |
RU2604133C1 (en) | Composition of vegetable origin in liposomal form | |
Sukandar et al. | EVALUATION OF ANTIFUNGAL ACTIVITY OF A 3-EXTRACT FORMULATION IN TOPICAL DOSAGE FORM AND ITS SAFETY ASPECT | |
Delgado et al. | Biomedical Effects of Popular Phytonutrients and Their Phytochemicals: A Comprehensive Review | |
AU2021449881A1 (en) | Non-steroidal topical composition and method thereof | |
Dixit | MEDICINAL IMPORTANCE OF PLANTS: AN OVERVIEW |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |